Company intelligence / Profile preview

Pharmalyte Solutions

Ownership: Private
Development stage: Other

Overview

Pharmalyte Solutions LLC develops small-molecule therapies targeting endocrinological and metabolic diseases. Its lead asset—magnesium L-lactate dihydrate—is currently in Phase 2 clinical trials for diabetes mellitus type 2 and hypomagnesemia. The company previously explored migraine disorders but this indication appears inactive now. There are no published results from these studies accessible without further login or subscription access.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pharmalyte Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmalyte Solutions.

Explore the full profile